Exchange Capital Management Inc. Sells 105 Shares of Eli Lilly and Company $LLY

Exchange Capital Management Inc. cut its stake in Eli Lilly and Company (NYSE:LLY) by 5.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,702 shares of the company’s stock after selling 105 shares during the quarter. Exchange Capital Management Inc.’s holdings in Eli Lilly and Company were worth $1,326,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of LLY. River Street Advisors LLC raised its holdings in Eli Lilly and Company by 12.2% in the 2nd quarter. River Street Advisors LLC now owns 3,563 shares of the company’s stock valued at $2,778,000 after acquiring an additional 387 shares during the period. Crews Bank & Trust lifted its holdings in shares of Eli Lilly and Company by 0.8% during the second quarter. Crews Bank & Trust now owns 6,029 shares of the company’s stock worth $4,700,000 after buying an additional 45 shares in the last quarter. Trinity Legacy Partners LLC increased its position in Eli Lilly and Company by 937.5% during the second quarter. Trinity Legacy Partners LLC now owns 2,905 shares of the company’s stock worth $2,295,000 after acquiring an additional 2,625 shares during the period. Hilltop National Bank acquired a new stake in Eli Lilly and Company in the 2nd quarter worth about $4,453,000. Finally, OLD Second National Bank of Aurora boosted its holdings in Eli Lilly and Company by 11.5% in the 2nd quarter. OLD Second National Bank of Aurora now owns 7,856 shares of the company’s stock valued at $6,124,000 after purchasing an additional 813 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Guggenheim cut their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Leerink Partners restated a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Insider Buying and Selling

In related news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.6%

Shares of LLY opened at $820.69 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The firm has a market cap of $776.75 billion, a price-to-earnings ratio of 53.64, a PEG ratio of 1.15 and a beta of 0.47. The business’s fifty day moving average is $734.03 and its 200-day moving average is $766.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.